Abstract | AIMS: METHODS: Patients with previously untreated, unresectable, and stage IIIA or IIIB NSCLC were eligible if they had a performance status of 0 or 1, were 75 years or younger, and had adequate organ function. Twenty-six patients (24 men and 2 women; median age, 66 years; age range, 42-75 years) were enrolled. Both cisplatin (40 mg/m(2)) and vinorelbine (20 mg/m(2)) were given on days 1 and 8 every 3 weeks. Beginning on day 2 of chemotherapy, thoracic radiotherapy was given for approximately 6 weeks (2 Gy per fraction; total dose, 60 Gy). RESULTS: Five of the 26 patients achieved a complete response, and 16 achieved a partial response for an overall response rate of 80.8% (95% confidence interval, 60.6-93.4%). The median survival time was 23 months (range, 4-43 months). Overall survival rates at 1 and 2 years were 80 and 56%, respectively. Hematologic toxicities included grade 3-4 neutropenia in 84.6% of patients, grade 3-4 thrombocytopenia in 3.8%, and grade 3-4 anemia in 61.5%. Two patients (7.7%) had grade 3 radiation esophagitis that resolved completely without dilation. Grade 3-4 radiation pneumonitis occurred in two patients (7.7%) and was treated with corticosteroids. Both patients had a good partial resolution of symptoms and radiographic abnormalities. There were no treatment-related deaths. The actual delivered dose intensities for both cisplatin and vinorelbine were 79.5%. Radiotherapy was completed in 96% of patients. CONCLUSION:
|
Authors | Takashi Hirose, Yoshihide Mizutani, Tohru Ohmori, Hiroo Ishida, Takamichi Hosaka, Kohichi Ando, Takao Shirai, Kentaro Okuda, Tsukasa Ohnishi, Naoya Horichi, Hayato Kubota, Mitsuru Adachi |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 58
Issue 3
Pg. 361-7
(Sep 2006)
ISSN: 0344-5704 [Print] Germany |
PMID | 16331494
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Vinblastine
- Cisplatin
- Vinorelbine
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects, therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology, radiotherapy)
- Cisplatin
(administration & dosage, adverse effects, therapeutic use)
- Combined Modality Therapy
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Humans
- Lung Neoplasms
(drug therapy, pathology, radiotherapy)
- Male
- Middle Aged
- Neoplasm Staging
- Radiation Dosage
- Thorax
- Treatment Outcome
- Vinblastine
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
- Vinorelbine
|